

Cite this: *Chem. Sci.*, 2019, 10, 5073

All publication charges for this article have been paid for by the Royal Society of Chemistry

Photoredox Ni-catalyzed peptide C(sp²)-O cross-coupling: from intermolecular reactions to side chain-to-tail macrocyclization†

Hyelee Lee,[†] Nicolas C. Boyer,^a Qiaolin Deng,^b Hai-Young Kim,[‡] Tomi K. Sawyer^d and Nunzio Sciammetta^{†*}

Ni/photoredox (4DPAIPN) dual catalysis enabled challenging peptide C(sp²)-O coupling reactions. Successful cross-coupling reactions were demonstrated with highly functionalized alcohols including side chains of amino acids (*i.e.*, serine, threonine, tyrosine), *trans*-4-hydroxy-L-proline, alkyl alcohols, alkynylated alcohols, and carbohydrates. Coupling reactions between bromobenzoyl-capped peptides containing various side chains and either a protected serine building block or a serine-containing dipeptide also proceeded efficiently. Chemoselective C-O coupling (over C-N) was achieved in intermolecular reactions in the presence of a C-terminal primary amide. Furthermore, by judicious structural design in combination with computational modeling, we demonstrated side chain-to-tail macrocyclization of peptides containing a β -turn motif *via* C-O coupling. The methodology developed in this work brings new opportunities for late-stage diversification of complex linear and macrocyclic peptides.

Received 8th February 2019

Accepted 8th April 2019

DOI: 10.1039/c9sc00694j

rsc.li/chemical-science

Introduction

Peptides are increasingly gaining attention as compelling therapeutic agents in drug discovery because of various attractive properties such as high binding affinities for flat or extended protein surfaces, exquisite target selectivities, good efficacy and safety profile. Recent successes in the development of peptide therapeutics and their increasing testing in clinical trials provide clear evidence that they are alternative modalities for challenging intracellular targets. They expand the druggable target space (*e.g.*, protein-protein interactions, allosteric binding sites) that historically has been inaccessible by traditional small molecules or biologics.¹

In structure-activity relationship (SAR) efforts surrounding peptide-based inhibitors, medicinal chemists routinely seek alteration of amino acid sequences, incorporation of D-amino acids, unnatural amino acids, N-methylation, peptidomimetics,

peptoids, *etc.* However, these approaches may be limited by their heavy reliance on the availability of costly building blocks. Therefore, elaboration *via* post-synthetic modification is of particular importance.² Macrocyclization is often utilized to improve metabolic and chemical stability, biological activity, selectivity and pharmacokinetic properties of peptide leads.³ The most common synthetic methods⁴ include macro-lactamization, ring-closing metathesis, azide-alkyne cycloaddition, and disulfide or thioether⁵ bond formations. More recently, *N*-arylation,⁶ *S*-arylation,⁷ and decarboxylative conjugate addition⁸ have been reported (Fig. 1A). These methods allow access to new amide, C(sp²)-C(sp²), C(sp²)-N, S-S, C(sp³)-S, C(sp²)-S, and C(sp³)-C(sp³) bonds. However, some of these scaffolds suffer from poor proteolytic and chemical stability (*e.g.*, thioether-containing peptides) and/or low cell permeability (*e.g.*, N-H-containing cross-linkage). To address these issues, we hypothesized that the underutilized ether linkage (C(sp²)-O)⁹ could provide proteolytic and chemical stability and nullify hydrogen-bond donor (HBD) ability, which can considerably affect cell permeating properties of peptides, in particular passive transport. Interestingly, macroetherification has been scarcely studied in the context of cyclic peptide synthesis. This is presumably due to synthetic challenges associated with the highly functionalized nature of peptides and the inherently low nucleophilicity of oxygen compared to other heteroatoms. The few reported examples of macroetherification of peptidic substrates are Ullmann-type reactions, S_NAr, S_N2-type displacement, or Tsuji-Trost reactions (Fig. 1B).¹⁰ These methodologies typically require excess amounts of strong bases, high

^aDepartment of Discovery Chemistry, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, USA. E-mail: hyelee.lee@merck.com; nunzio.sciammetta@merck.com

^bComputational and Structural Chemistry, MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, USA

^cProcess and Analytical Research and Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, USA

^dChemistry Capabilities for Accelerating Therapeutics, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc00694j

‡ Present address: Analytical Research and Development, Pfizer Inc., Andover, Massachusetts 01810, USA.




Table 1 Control experiments. 0.1 mmol **1** scale, 1.5 equiv. **2c** using either MSD photoreactor²¹ or Penn Optical photoreactor

Entry	Variations from above	Yield ^a (%)
1	Conditions above	81
2	NiCl ₂ ·glyme instead of NiBr ₂ ·glyme	61 ^b
3	Ir[dF(CF ₃)ppy] ₂ (dtbbpy)PF ₆ instead of 4DPAIPN	61
4	20 equiv. water added	24
5	5 equiv. water instead of 2c	43 ^c
6	4Å molecular sieves added	77
7	5 mol% 4DPAIPN	77
8	No quinuclidine	64

^a Yields were determined by ¹H NMR spectroscopy against 1,3,5-trimethoxybenzene as an internal standard. ^b ArCl side-product was observed. ^c Yield of ArOH.

entry 3) compared to 4DPAIPN (81%). One noticeable difference between the iridium catalyst and 4DPAIPN is that in its reduced form, 4DPAIPN is a better reductant than the Ir-catalyst ($E_{1/2}^{\text{red}}[\text{PC}/\text{PC}^{\cdot-}] = -1.52 \text{ V vs. } E_{1/2}^{\text{red}}[\text{Ir}^{\text{III}}/\text{Ir}^{\text{II}}] = -1.37 \text{ V}$), possibly facilitating single electron reduction of Ni(I) to Ni(0) to close the

Table 2 Substrate scope of alcohols in intermolecular C–O coupling. 0.1 mmol **1** scale, 1.5 equiv. **2** using either MSD photoreactor or Penn Optical photoreactor. Yields were determined by ¹H NMR spectroscopy against 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are reported in parentheses after purification using either preparative reverse-phase HPLC or automated normal-phase column chromatography




^a Isolated yield for 0.5 mmol **1** scale. ^b 3.0 equiv. alcohol were used. ^c 2.0 equiv. alcohol were used. ^d C–N coupling side-product was isolated (<5% isolated yield). ND, not determined.

dual catalytic cycle.¹⁹ The major side-product was the phenol derivative, likely originating from the reaction of **1** with adventitious water present in the reaction mixture. Addition of water was detrimental to productivity of the desired C–O coupling (entry 4). In this case, the formation of the phenol side-product was not noticeable but there were substantial amounts of unreacted aryl bromide starting material, which may arise from quenching of the nickel catalyst by the excess water. Entry 5 clearly supports existence of a competing pathway where water can react with **1** to generate the corresponding phenol. Addition of molecular sieves did not significantly improve reaction efficiency, possibly due to much of the incident light being scattered off by the suspended particles (entry 6). Increasing photocatalyst loading was not beneficial (entry 7). In the absence of quinuclidine, the yield was diminished (81% to 64%), possibly because of the beneficial role of quinuclidine as an electron shuttle and/or reductant (entry 8).^{12,20}

With optimized reaction conditions in hand, we examined the substrate scope of various alcohols in an intermolecular C–O coupling. Aliphatic alcohols successfully coupled with aryl bromide dipeptide **1**, giving the desired products in 97% and 58% yield (Table 2, **3a** and **3b**), respectively. Surprisingly, a seemingly minor change in the ester protecting group of **1**–

Table 3 Substrate scope of bromobenzoyl-capped peptides in intermolecular C–O coupling. 0.1 mmol ArBr scale, 1.5 equiv. alcohol. Yields were determined by ¹H NMR spectroscopy against 1,3,5-trimethoxybenzene as an internal standard. Isolated yields are reported in parentheses after purification using preparative reverse-phase HPLC



^a 0.05 mmol ArBr scale. ND, not determined.



serine – switching from *tert*-butyl (**2c**) to methyl (**2d**) – led to diminished yield (81% to 53%). This may arise from instability of both starting material (**2d**) (hydrolysis by residual water to the corresponding acid) and product (**3d**) (β -elimination). The secondary alcohol from protected *trans*-4-hydroxy-*L*-proline (**2e**) provided the desired ether linkage in moderate yield (**3e**, 52%). 1,3-Propanediol (**2f**) was also examined to evaluate the formation of the corresponding di-ether. Using a 2 : 1 ratio of **1** : **2f**, the major product was the mono-ether adduct (**3f**, 63% and **3f'**, 25%). We then tested tolerance to functional groups commonly utilized in bioconjugation chemistry. Terminal alkyne **2g** was tolerated (**3g**, 62%), whereas azide **2h** was incompatible with the reaction conditions. Protected 6-amino-1-hexanol (**2i**) and α -D-galactopyranose (**2j**) can also undergo the desired coupling reactions with good efficiency (**3i**, 44% and **3j**, 54%). We also explored the cross-coupling of hydroxyl-containing dipeptides (**2k–2n**). Serine-containing dipeptides were successfully coupled with **1** (**3k**, 60% and **3l**, 38%). Reaction between **1** and the more sterically demanding threonine-containing peptide **2m** afforded


the desired alkyl aryl ether in moderate yield, likely due to poor solubility of **2m**.

An unexpected but intriguing result is the successful coupling of tyrosine-containing dipeptide **2n**, furnishing a $C(sp^2)–O–C(sp^2)$ motif abundant in natural products and important glycopeptide antibiotics (*e.g.*, vancomycin family). Compared to aliphatic alcohol substrates, there may be an alternative mechanistic pathway in play for tyrosine-based substrates (Fig. S4†). Considering the redox potential and bond dissociation free energy (BDFE) of the phenolic O–H bond being relatively high,²² the possibility of direct hydrogen atom transfer (HAT) mechanism is improbable. Alternatively, a transient phenoxy radical could be generated by either oxidation of phenolate or proton-coupled electron transfer (PCET), which is widely discussed in Tyr redox chemistry.²³


We then turned our attention to the substrate scope for the bromobenzoyl-capped peptides. By changing the substituent pattern of the bromide position from *para* (**1**) to *meta* (**5**), the reaction efficiency was moderately reduced for both coupling

A. Two proposed model systems for macrocyclization and their conformational sampling and experimental results:

Design 1)




Highly flexible, disorganized, extended conformation




12a
3% conversion
(UPLC-MS analysis)

Design 2)




Preorganized via intramolecular H-bond



13a
67% isolated yield
(7:3 C–O/C–N)

B. Key HMBC correlations for C–O cyclized peptide **13a**:



C. Peptide macrocyclization:




Fig. 3 Macrocyclization of peptides with a β -hairpin motif (design 2) via Ni-catalyzed photoredox C–O coupling (modeling and experimental results). (A) Two proposed designs for macrocyclization. (B) Key $^1\text{H}–^{13}\text{C}$ HMBC correlations confirming C (sp^2)–O bond formation for **13a**. (C) Examples of macrocyclic peptides. Isolated yields are reported after purification using preparative reverse-phase HPLC. General reaction conditions: 0.05 mmol scale, 1 equiv. K_2CO_3 , 10 mol% 4DPAIPN, 5 mol% quinuclidine, 20 mol% $\text{NiBr}_2 \cdot \text{glyme}$, 20 mol% dtbbpy, 2 : 1 MeCN/DMSO (0.005 M), RT, 24 h, 450 nm blue LEDs using MSD photoreactor.



counterparts **2c** and **2k** (Table 3, **5a**, 54% vs. **3c**, 81% and **5b**, 41% vs. **3k**, 60%). Attenuated reactivity of **5** could be imputed to a slower oxidative addition of Ni(0) associated with the electron-withdrawing group at the *meta* position, in addition to greater sterics around the nickel coordination site compared to the *para*-substituted substrate. Tripeptide **6** was successfully coupled with either **2c** or **2k** to give desired products, **6a** or **6b**, respectively. Importantly, dipeptides bearing various functional groups (indole, carboxylic acid, amide, amine, thioethers from the side chains of Trp, Glu, Gln, Lys, Met) were also competent partners for peptide C–O coupling (**7a–11a** and **7b–11b**).

To investigate peptide macrocyclization through C–O cross-coupling, we designed two model systems (Fig. 3A): (1) a tripeptide C-terminally modified with 4-amino-1-butanol (**12**) and (2) a pentapeptide containing the turn-inducer motif D-Pro–L-Pro (**13**).²⁴ The former design affords conformational flexibility between the two reactive sites, while the latter has a higher propensity to form a β -hairpin that could promote substrate preorganization through intramolecular hydrogen bonds. To assess feasibility of such macrocyclization, we utilized conformational sampling to calculate accessible conformations of model system of linear substrates. A hundred thousand conformations were generated by using our in-house implementation of the distance geometry approach (Fig. S5†).²⁵ The conformations were minimized by Merck Molecular Force Field (MMFFs)²⁶ and clustered into 1500 conformations. The conformations within 2 kcal mol^{−1} compared to the lowest energy are exemplified in Fig. 3A. Linear precursor **12** appears to be highly flexible and disorganized while **13** is relatively well-organized with clear intramolecular hydrogen bonding interactions (yellow dashed lines in Fig. 3A, design 2). To our delight, Ni-catalyzed photoredox macrocyclization of **13** afforded the desired cyclized product in 67% isolated yield with two separable regioisomers (7 : 3 C–O/C–N connectivity) as confirmed by 1D and 2D NMR analyses.²⁷ However, reactions attempted with **12** resulted primarily in starting material recovery, in addition to the formation of debrominated and phenol side-products (3% conversion to the cyclized product observed by UPLC-MS analysis). With the success in macrocyclization of peptide **13** via C–O cross-coupling, we further examined substrates containing the D-Pro–L-Pro motif. Inversion of stereochemical configuration at the C-terminus was well tolerated with slightly diminished selectivity (**14a**, 67%, 6 : 4 C–O/C–N). Modification to methyl ester at the C-terminus allowed formation of the C–O macrocyclic peptide **15a** in 42% yield. Interestingly, by eliminating the hydroxymethylene side chain (Ser to Gly), the C–N cross-coupling product was formed exclusively in good yield (**16a**, 41%). A pentapeptide containing Trp and Glu residues also underwent efficient macrocyclization (**17a**, 45%, 6 : 4 C–O/C–N). Macrocyclization of a longer peptide (7-mer) proceeded well, furnishing the desired C–O coupling product to give the 26-membered macrocyclic peptide **18a** (27%).

Conclusions

We have demonstrated that a challenging peptide C–O cross-coupling can be achieved by Ni-catalyzed photoredox catalysis. Successful intermolecular etherification was reported between

various alcohols and bromobenzoyl-capped peptides with high chemoselectivity and good yields. Strategic structural designs with the aid of computational modeling enabled side chain-to-tail macrocyclization. This work expands chemical space to broaden the applicability of cyclic peptides as powerful ligands and potential leads for challenging targets. Furthermore, we plan to utilize such synthetic methodology to advance macrocyclic peptides and elucidate their structure-cell permeability relationships. Specifically, efforts towards the direct comparison of cell permeability and stability of C–O vs. C–N or C–S containing macrocyclic peptides are ongoing. Results will be reported in due course.

Conflicts of interest

The authors declare no competing financial interests.

Acknowledgements

This work was supported by the Postdoctoral Research Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. We thank Prof. David W. C. MacMillan and his group for helpful discussions. We also thank Valerie Shurleff and Brandon Vara for helpful discussions and reviewing this paper. We greatly acknowledge Miroslawa Darlak, Spencer McMinn, Lisa Nogle, Mark Pietrafitta, David Smith for purification of the final compounds. We also thank Adam Beard and Shishi Lin for HRMS and HTE supports, respectively.

References

- For select reviews, see: (a) P. G. Dougherty, Z. Qian and D. Pei, *Biochem. J.*, 2017, **474**, 1109; (b) D. E. Scott, A. R. Bayly, C. Abell and J. Skidmore, *Nat. Rev. Drug Discovery*, 2016, **15**, 533; (c) N. Qvit, S. J. S. Rubin, T. J. Urban, D. Mochly-Rosen and E. R. Gross, *Drug Discovery Today*, 2017, **22**, 454; (d) J. L. Lau and M. K. Dunn, *Bioorg. Med. Chem.*, 2018, **26**, 2700.
- (a) L. J. Walport, R. Obexer and H. Suga, *Curr. Opin. Biotechnol.*, 2017, **48**, 242; (b) L. R. Malins, *Curr. Opin. Chem. Biol.*, 2018, **46**, 25.
- (a) E. M. Driggers, S. P. Hale, J. Lee and N. K. Terrett, *Nat. Rev. Drug Discovery*, 2008, **7**, 608; (b) E. Marsault and M. L. Peterson, *J. Med. Chem.*, 2011, **54**, 1961.
- C. J. White and A. K. Yudin, *Nat. Chem.*, 2011, **3**, 509.
- (a) T. Passioura and H. Suga, *Chem.–Eur. J.*, 2013, **19**, 6530; (b) K. Ito, T. Passioura and H. Suga, *Molecules*, 2013, **18**, 3502.
- B. A. Hopkins, G. F. Smith and N. Sciammetta, *Org. Lett.*, 2016, **18**, 4072.
- (a) K. Kubota, P. Dai, B. L. Pentelute and S. L. Buchwald, *J. Am. Chem. Soc.*, 2018, **140**, 3128; (b) A. J. Rojas, C. Zhang, E. V. Vinogradova, N. H. Buchwald, J. Reilly, B. L. Pentelute and S. L. Buchwald, *Chem. Sci.*, 2017, **8**, 4257.
- J. McCarver, J. X. Qiao, J. Carpenter, R. M. Borzilleri, M. A. Poss, M. D. Eastgate, M. Miller and D. W. C. MacMillan, *Angew. Chem., Int. Ed.*, 2017, **56**, 728.



- 9 Only few examples exist for the synthesis of C(sp²)-O bond containing macrocyclic natural products or peptide drugs and they are shown in Fig. 1B. (a) H. Uchiro, R. Kato, Y. Arai, M. Hasegawa and Y. Kobayakawa, *Org. Lett.*, 2011, **13**, 6268; (b) J. Kuethe, Y.-L. Zhong, N. Yasuda, G. Beutner, K. Linn, M. Kim, B. Marcune, S. D. Dreher, G. Humphrey and T. Pei, *Org. Lett.*, 2013, **15**, 4174.
- 10 (a) D. L. Boger and D. Yohannes, *J. Org. Chem.*, 1991, **56**, 1763; (b) D. L. Boger, Y. Nomoto and B. R. Teegarden, *J. Org. Chem.*, 1993, **58**, 1425; (c) Q. Cai, B. Zou and D. Ma, *Angew. Chem., Int. Ed.*, 2006, **45**, 1276; (d) D. A. Evans, M. R. Wood, B. W. Trotter, T. I. Richardson, J. C. Barrow and J. L. Katz, *Angew. Chem., Int. Ed.*, 1998, **37**, 2700; (e) A. V. R. Ram, K. L. Reddy, A. S. Ram, T. V. S. K. Vittal, M. M. Reddy and P. L. Pathi, *Tetrahedron Lett.*, 1996, **37**, 3023; (f) R. Beugelmans, G. P. Singh, M. Bois-Choussy, J. Chastanet and J. Zhu, *J. Org. Chem.*, 1994, **59**, 5535; (g) D. P. Fairlie, J. D. A. Tyndall, R. C. Reid, A. K. Wong, G. Abbenante, M. J. Scanlon, D. R. March, D. A. Bergman, C. L. L. Chai and B. A. Burkett, *J. Med. Chem.*, 2000, **43**, 1271; (h) K. V. Lawson, T. E. Rose and P. G. Harran, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, E3753.
- 11 (a) J. N. deGruyter, L. R. Malins and P. S. Baran, *Biochemistry*, 2017, **56**, 3863; (b) C. D. Spicer and B. G. Davis, *Nat. Commun.*, 2014, **5**, 4740; (c) X. Chen, K. Muthoosamy, A. Pfisterer, B. Neumann and T. Weil, *Bioconjugate Chem.*, 2012, **23**, 500; (d) H. Chen, R. Huang, Z. Li, W. Zhu, J. Chen, Y. Zhan and B. Jiang, *Org. Biomol. Chem.*, 2017, **15**, 7339; (e) G. Lautrette, F. Touti, H. G. Lee, P. Dai and B. L. Pentelute, *J. Am. Chem. Soc.*, 2016, **138**, 8340.
- 12 J. A. Terrett, J. D. Cuthbertson, V. W. Shurtleff and D. W. C. MacMillan, *Nature*, 2015, **524**, 330.
- 13 While there is an increasing number of reports for peptide modifications by photoredox catalytic reactions, only a few examples were reported using Ni/photoredox dual-catalyzed reactions, (a) B. A. Vara, X. Li, S. Berritt, C. R. Walters, E. J. Petersson and G. A. Molander, *Chem. Sci.*, 2018, **9**, 336; select examples for photoredox catalytic reactions of peptides, (b) S. Bloom, C. Liu, D. K. Kölmel, J. X. Qiao, Y. Zhang, M. A. Poss, W. R. Ewing and D. W. C. MacMillan, *Nat. Chem.*, 2018, **10**, 205; (c) Y. Yu, L.-K. Zhang, A. V. Buevich, G. Li, H. Tang, P. Vachal, S. L. Colletti and Z.-C. Shi, *J. Am. Chem. Soc.*, 2018, **140**, 6797; (d) N. Ichiishi, J. P. Caldwell, M. Lin, W. Zhong, X. Zhu, E. Streckfuss, H.-Y. Kim, C. A. Parish and S. W. Krska, *Chem. Sci.*, 2018, **9**, 4168.
- 14 (a) H. Sigel and R. B. Martin, *Chem. Rev.*, 1982, **82**, 385; (b) J. Schapp, K. Haas, K. Sünkel and W. Beck, *Eur. J. Inorg. Chem.*, 2003, **2003**, 3745; (c) M. K. Kim and A. E. Martell, *J. Am. Chem. Soc.*, 1967, **89**, 5138.
- 15 J. Luo and J. Zhang, *ACS Catal.*, 2016, **6**, 873.
- 16 Details can be found in ESI.†
- 17 A. B. Santanilla, E. L. Regalado, T. Pereira, M. Shevlin, K. Bateman, L.-C. Campeau, J. Schneeweis, S. Berritt, Z.-C. Shi, P. Nantermet, Y. Liu, R. Helmy, C. J. Welch, P. Vachal, I. W. Davies, T. Cernak and S. D. Dreher, *Science*, 2015, **347**, 49.
- 18 T. T. Tsou and J. K. Kochi, *J. Am. Chem. Soc.*, 1979, **101**, 6319.
- 19 While this may be true, the redox potentials of photocatalysts' excited state would also play roles in reaction kinetics ($E_{1/2}^{\text{red}}[\text{PC}^*/\text{P}^{\cdot-}] = +1.10 \text{ V}$ vs. $E_{1/2}^{\text{red}}[*\text{Ir}^{\text{III}}/\text{Ir}^{\text{II}}] = +1.21 \text{ V}$). The photoexcited $*\text{Ir}^{\text{III}}$ being a stronger oxidant would facilitate SET oxidation step from Ni(II) to Ni(III) in the catalytic cycle. $E_{1/2} =$ A half-reaction redox potential in volts versus the saturated calomel electrode (SCE) in acetonitrile, PC = 4DPAIPN, Ir = Ir[dF(CF₃)ppyl]₂(dtbbpy)PF₆. The values are from ref. 15 and M. S. Lowry, J. I. Goldsmith, J. D. Slinker, R. Rohl, R. A. Pascal, G. G. Malliaras and S. Bernhard, *Chem. Mater.*, 2005, **17**, 5712.
- 20 (a) J. L. Jeffrey, J. A. Terrett and D. W. C. MacMillan, *Science*, 2015, **349**, 1532; (b) J. Twilton, M. Christensen, D. A. DiRocco, R. T. Ruck, I. W. Davies and D. W. C. MacMillan, *Angew. Chem., Int. Ed.*, 2018, **57**, 5369.
- 21 C. C. Le, M. K. Wismer, Z.-C. Shi, R. Zhang, D. V. Conway, G. Li, P. Vachal, I. W. Davies and D. W. C. MacMillan, *ACS Cent. Sci.*, 2017, **3**, 647.
- 22 J. J. Warren, T. A. Tronic and J. M. Mayer, *Chem. Rev.*, 2010, **110**, 6961.
- 23 (a) J. J. Warren, J. R. Winkler and H. B. Gray, *FEBS Lett.*, 2012, **586**, 596; (b) B. W. Berry, M. C. Martínez-Rivera and C. Tommos, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 9739; (c) C. Li and M. Z. Hoffman, *J. Phys. Chem. B*, 1999, **103**, 6653.
- 24 M. Favre, K. Moehle, L. Jiang, B. Pfeiffer and J. A. Robinson, *J. Am. Chem. Soc.*, 1999, **121**, 2679.
- 25 G. M. Crippen and T. F. Havel, *Distance Geometry and Molecular Conformation*, Wiley, New York, 1988.
- 26 T. A. Halgren, *J. Comput. Chem.*, 1999, **20**, 730.
- 27 The C-N coupling product is from the reaction between aryl bromide and the carboxamide at the C-terminus.

